Deregulation limits attacked as Japan stakes ground over online drug sales
This article was originally published in Scrip
Japan's government has decided to press ahead with deregulating the online sale of most over-the-counter (OTC) medicines while moving more cautiously for certain switched prescription products, in steps that nevertheless did not go far enough to satisfy the outspoken head of the country's largest internet shopping mall.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.